| Arthritis, Psoriatic
Cosentyx vs Enbrel
Side-by-side clinical, coverage, and cost comparison for arthritis, psoriatic.Deep comparison between: Cosentyx vs Enbrel with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsEnbrel has a higher rate of injection site reactions vs Cosentyx based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Enbrel but not Cosentyx, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Cosentyx
Enbrel
At A Glance
SC injection
Every 4 weeks
IL-17A antagonist
SC injection
Once weekly
TNF-alpha inhibitor
Indications
- Psoriasis vulgaris
- Arthritis, Psoriatic
- Ankylosing spondylitis
- Non-Radiographic Axial Spondyloarthritis
- Enthesitis-Related Arthritis
- Hidradenitis Suppurativa
- Rheumatoid Arthritis
- Arthritis, Psoriatic
- Ankylosing spondylitis
- Psoriasis vulgaris
- Polyarticular Juvenile Idiopathic Arthritis, Rheumatoid Factor Negative
- Juvenile psoriatic arthritis
Dosing
Psoriasis vulgaris 300 mg SC at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter; 150 mg may be acceptable for some adults; pediatric patients 6 years and older receive weight-based dosing on the same schedule.
Arthritis, Psoriatic 150 mg SC with or without a loading dose at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter; may increase to 300 mg SC every 4 weeks if active disease persists; IV option: 6 mg/kg loading at Week 0, then 1.75 mg/kg every 4 weeks infused over 30 minutes.
Ankylosing spondylitis 150 mg SC with or without a loading dose at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter; may increase to 300 mg SC every 4 weeks if active disease persists; IV option: 6 mg/kg loading at Week 0, then 1.75 mg/kg every 4 weeks infused over 30 minutes.
Non-Radiographic Axial Spondyloarthritis 150 mg SC with or without a loading dose at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter; IV option: 6 mg/kg loading at Week 0, then 1.75 mg/kg every 4 weeks infused over 30 minutes.
Enthesitis-Related Arthritis Weight-based SC dosing for pediatric patients 4 years and older at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter; 150 mg for patients >= 50 kg.
Hidradenitis Suppurativa 300 mg SC at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter; may increase to every 2 weeks in adults with inadequate response; pediatric patients 12 years and older receive weight-based dosing every 4 weeks.
Rheumatoid Arthritis, Arthritis, Psoriatic, Ankylosing spondylitis 50 mg SC once weekly, with or without MTX
Psoriasis vulgaris 50 mg SC twice weekly for 3 months (loading), then 50 mg SC once weekly (maintenance)
Polyarticular Juvenile Idiopathic Arthritis, Rheumatoid Factor Negative, Juvenile psoriatic arthritis 0.8 mg/kg SC once weekly, maximum 50 mg per week
Contraindications
- Previous serious hypersensitivity reaction to secukinumab or any excipient in COSENTYX
- Sepsis
Adverse Reactions
Most common (>=1%) nasopharyngitis, diarrhea, upper respiratory tract infection, rhinitis, oral herpes, pharyngitis, urticaria, rhinorrhea
Serious infections (including serious infections and sepsis), inflammatory bowel disease (Crohn's disease and ulcerative colitis), neutropenia, anaphylaxis, angioedema
Postmarketing anaphylaxis, angioedema, systemic vasculitis, eczematous eruptions, cutaneous vasculitis, pyoderma gangrenosum, opportunistic infections including esophageal candidiasis, cytomegalovirus gastroenteritis/colitis, Pneumocystis jiroveci pneumonia, hepatitis B virus reactivation, histoplasmosis, toxoplasmosis
Most common Infections (upper respiratory tract infection, sinusitis, influenza), injection site reactions (erythema, itching, pain, swelling)
Serious Serious infections (pneumonia, cellulitis, septic arthritis, sepsis), neurologic events, congestive heart failure, hematologic events
Postmarketing Pancytopenia, anemia, leukopenia, neutropenia, thrombocytopenia, aplastic anemia, congestive heart failure, inflammatory bowel disease, angioedema, autoimmune hepatitis, macrophage activation syndrome, systemic vasculitis, sarcoidosis, lupus-like syndrome, melanoma, non-melanoma skin cancers, Merkel cell carcinoma, convulsions, multiple sclerosis, demyelination, optic neuritis, transverse myelitis, uveitis, scleritis, glomerulonephritis, interstitial lung disease, Stevens-Johnson syndrome, toxic epidermal necrolysis, opportunistic infections
Pharmacology
Secukinumab is a human IgG1 monoclonal antibody that selectively binds to the IL-17A cytokine and inhibits its interaction with the IL-17 receptor, suppressing the release of proinflammatory cytokines and chemokines involved in inflammatory and immune responses.
Etanercept is a dimeric soluble form of the human p75 TNF receptor that inhibits binding of TNF-alpha and TNF-beta (lymphotoxin alpha) to cell surface TNF receptors, rendering TNF biologically inactive and modulating downstream inflammatory responses including adhesion molecule expression, cytokine levels, and matrix metalloproteinase levels.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Cosentyx
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (9/12)
Enbrel
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (12/12) · Qty limit (11/12)
UnitedHealthcare
Cosentyx
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (1/8) · Qty limit (4/8)
Enbrel
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (6/8) · Qty limit (6/8)
Humana
Cosentyx
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (0/3)
Enbrel
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Ankylosing Spondylitis: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Final cost depends on formulary coverage
No savings programs available for Enbrel.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CosentyxView full Cosentyx profile
EnbrelView full Enbrel profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.